Navigation Links
MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 4, 2009
Date:4/27/2009

VALENCIA, Calif., April 27 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2009 first quarter financial results on Monday, May 4, 2009.

Management of the Company will host a conference call to discuss the first quarter financial results and other Company developments at 4:00 PM EDT on May 4, 2009. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Matthew Pfeffer and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com.

A telephone replay of the call will be accessible for approximately fourteen days following completion of the call by dialing (888) 566-0513 or (203) 369-3063. A replay will also be available on MannKind's website for fourteen days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFRESA(R), an ultra rapid-acting insulin and MKC253, an inhaled formulation of human GLP-1. MannKind also has two cancer immunotherapeutic products in clinical development. MannKind maintains a website at http://www.mannkindcorp.com to which the company regularly posts copies of its press releases as well as additional information. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the SEC or posts certain other information to the website.


'/>"/>
SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MannKind Submits NDA for AFRESA for Treatment of Diabetes
2. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
3. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
4. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
5. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
6. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
7. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
8. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
9. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
10. MannKind to Present at the UBS Global Life Sciences Conference
11. MannKind Corporation Reports Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2017)... ... September 17, 2017 , ... ... South Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational New ... the Middle East Respiratory Syndrome coronavirus (MERS-CoV). The study in Korea represents the ...
(Date:9/14/2017)... Lafayette, Ind (PRWEB) , ... ... ... of AMRI’s Global Analytical Services, formally introduces its flexible scientist program (FSP)-- ... offers volume-based, preferred-rate pricing. The FSP, which combines SSCI’s extensive project-based analytical ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... portfolio, clinically-relevant starting and ancillary materials that generate unprecedented efficiencies in adult ... therapies. The CliniControl product portfolio will radically simplify major steps in product ...
(Date:9/14/2017)... ... 2017 , ... AxioMed is pleased to announce the success ... completed the procedure on a 35-year-old female patient suffering from degenerative disc disease ... L5-S1. The patient failed conservative treatments prior to undergoing surgery. , Dr. Yang ...
Breaking Biology Technology:
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):